What keeps weight off after GLP-1 medication stops is the eating pattern, training and habits built while it was working, because the medicine's appetite effect stops with it. When the STEP 1 extension stopped the medication overnight, about two-thirds of the lost weight returned within a year (Wilding 2022); individual results vary. The GetLean GLP-1 Taper Plan builds those habits first, with daily WhatsApp coaching.
Everything else about a maintenance phase — the eating pattern, the training, the muscle that has been kept or lost — carries on exactly as it was, which is why what has been built during treatment matters more at this point than at any other. The trials measured body weight, not appetite.
Maintenance phase: the period after active weight loss ends, when the goal changes from losing more to holding what has been lost. After medication stops, it is also the period when behaviour has to hold the result on its own.
What actually stops when the medication stops?
The drug clears from the body over a matter of weeks, and the appetite effect it was producing stops being produced.
The pharmacology is straightforward. Semaglutide has an elimination half-life of about one week and is present in the circulation for roughly five to seven weeks after a last 2.4 mg dose (DailyMed); tirzepatide's elimination half-life is about five to six days (DailyMed). A half-life describes drug concentration rather than the duration of any downstream physiological effect, so those numbers say when the medicine is gone, not when its consequences finish unwinding.
Here is the part that gets stated more confidently than the evidence allows. No GLP-1 withdrawal trial measured appetite. The STEP 1 extension, STEP 4 and SURMOUNT-4 all measured body weight and cardiometabolic markers; none of them measured hunger, craving, food intake or fullness after treatment ended. So "appetite comes back when you stop" is a reasonable mechanistic inference from a drug leaving the system — it is not a trial finding. We go through that gap in detail in appetite after stopping GLP-1.
What this means practically is that the size of the change a person experiences is not something the literature can predict for them.
What the withdrawal trials actually measured
Body weight, waist and cardiometabolic markers, after the medication was taken away, by stopping it or by switching people to placebo.
In the STEP 1 extension, participants had reached a mean 17.3% weight loss by week 68. The medication and the lifestyle support then stopped on the same day, with no taper, and about two-thirds of the lost weight returned within a year, leaving the group 5.6% below its original starting weight at week 120 (Wilding 2022). The trial reports a mean with a standard deviation of 7.7 percentage points, so the two-thirds figure describes a group average around which individuals varied considerably.
That overnight stop is the scenario a planned exit is designed around. Even after it, the group had not returned to square one.
What is known about people who hold a loss?
More than most people assume, and some of it comes from people who had taken a GLP-1 medication.
In a Copenhagen randomised trial that followed adults for a year after treatment ended, those who had combined a GLP-1 medication with supervised exercise were more likely than those who had taken the medication alone to still hold a loss of at least 10% of their starting weight (Jensen 2024). The medication was liraglutide, an earlier GLP-1 medicine, and the initial loss came from a low-calorie diet. In the same trial, weight regain in the year after stopping was 6.0 kg larger after the medication alone than after supervised exercise alone.
The habits that predict keeping weight off
The main source on what maintainers do is the National Weight Control Registry, a self-selected group of volunteers who had lost at least 13.6 kg and kept it off for five years on average. It records what successful maintainers report doing rather than what caused their success, and what it reports is coherent. Registry members had lost a mean of 30 kg, and reported a low-fat eating pattern with about 24% of energy from fat alongside a high level of physical activity, roughly an hour a day (Klem 1997). That is a lot, and it is one of the most consistent findings in the literature. The specific macronutrient framing reflects the era; the more durable observation is consistency rather than a particular composition. Followed for a year, 59% of members maintained their loss and 35% gained; the factors associated with regaining were more recent losses (under two years rather than two years or more), larger losses relative to maximum weight, and higher scores for depression, dietary disinhibition and binge eating (McGuire 1999). Those who regained showed decreases in energy expenditure and dietary restraint, and increases in dietary fat, hunger and disinhibited eating (McGuire 1999). A separate registry analysis found that members who reduced how often they weighed themselves regained 4.0 kg over a year, against 1.1 kg among those who weighed themselves more often (Butryn 2007). The association held independently of other measured factors (Butryn 2007). Worth being precise: this is the correct source for a self-monitoring claim. The founding registry papers do not report one.
The time finding is the one worth internalising. Maintenance appears to get easier with duration: a review estimates that more than 20% of people with overweight or obesity achieve an intentional 10% loss held for at least a year, and notes that once a loss has been held for two to five years the chance of longer-term success rises substantially (Wing and Hill 2001). The hardest period is the one immediately after the loss, which is also the period in which a medication is most often stopped.
On activity specifically, the ACSM position stand associates more than 250 minutes a week with better maintenance, on cross-sectional and prospective evidence (Donnelly 2009). Two hundred and fifty minutes is around 35 minutes a day. It is more than the general activity guideline, and it is roughly consistent with what registry maintainers report.
What the maintenance evidence in this section reports, and what kind of evidence each finding is.
| Finding | Type of evidence | Source |
|---|---|---|
| Adults who had combined a GLP-1 medication with supervised exercise were more likely than those who had taken the medication alone to still hold a loss of at least 10% a year after treatment ended | Randomised trial; the medication was liraglutide, and the initial loss came from a low-calorie diet | Jensen 2024 |
| Members had lost a mean of 30 kg and reported about 24% of energy from fat alongside roughly an hour a day of physical activity | Self-selected registry of people who had lost at least 13.6 kg and kept it off for five years on average | Klem 1997 |
| Followed for a year, 59% of members maintained their loss and 35% gained; more recent losses (under two years) were among the factors associated with regaining | Registry | McGuire 1999 |
| Members who reduced how often they weighed themselves regained 4.0 kg over a year, against 1.1 kg among those who weighed themselves more often | Registry analysis | Butryn 2007 |
| Estimates that more than 20% of people with overweight or obesity achieve an intentional 10% loss held for at least a year; once a loss has been held for two to five years, the chance of longer-term success rises substantially | Review | Wing and Hill 2001 |
| More than 250 minutes a week of physical activity associated with better maintenance | Position stand, on cross-sectional and prospective evidence | Donnelly 2009 |
What has to carry the result instead?
The things that do not stop when a prescription does.
Muscle that is still there. Lean mass was statistically unchanged in the trials where resistance training accompanied caloric restriction (Lopez 2022). Muscle preserved during the losing phase is muscle that is still working during the maintenance phase, and it is the one asset that cannot be assembled quickly at the end. Muscle carried into maintenance is a structural advantage the registry never measured.
An eating pattern that has become ordinary. During treatment, a smaller intake is partly the medication's doing. In maintenance it has to be structural — what is bought, what is cooked, what gets ordered at a hawker centre — because the pharmacological help has stopped.
A measurement habit. Self-weighing is the cheapest early-warning system there is, and the registry association above is the reason to keep it running rather than stopping when active treatment does.
There is an obvious tension between that finding and our own advice that the scale is a poor progress measure. Both can be true. During active weight loss, the scale misleads about composition. During maintenance, it is an early-warning system for drift — a different job, and one it does well.
Activity that survives a bad week. The 250-minute figure is an association rather than a proven threshold, but the direction of the evidence is consistent, and a routine that only works in ideal conditions will not survive the first busy month.
Is a gentler exit possible?
Yes. The withdrawal trials took the medication away, by stopping it or by switching people to placebo; a planned exit steps it down.
At GetLean the taper is planned from the first consultation and set at Dr Quek's monthly reviews as the response comes in, rather than written as a fixed schedule on day one. The habits are built with daily WhatsApp coaching while the medication is still quieting appetite. The dose then comes down gradually under his guidance, towards the lowest effective dose, rather than in a cliff-edge stop, which allows appetite to adjust incrementally while the eating pattern, the training and the measurement habit take over.
Stepping down is a different picture from stopping. In SURMOUNT-MAINTAIN, adults who stepped down to a lower dose of tirzepatide after 60 weeks were still 16.6% below their starting weight a year later (Horn 2026). We set out how a planned taper works in tapering off GLP-1.
At GetLean, the programme is designed to end: our philosophy is that GLP-1 medication should act as a catalyst — not something to depend on indefinitely. The plan for coming off is the GetLean GLP-1 Taper Plan: after hitting your goal weight with the right nutrition and exercise habits built, the dose is stepped down at Dr Quek's monthly reviews towards your lowest effective dose and, where clinically appropriate, off the medication. The maintenance phase is what the programme is built around: it is the point at which the plan around the medication has to work without it, which is why that plan starts on day one. Individual results vary, and clinical-trial figures describe the populations studied. Never change or stop a prescribed medication on your own; that is a conversation with the doctor who prescribed it.
What happens after the taper at GetLean?
Finishing the taper does not have to end the support. After the taper, a patient can keep the daily WhatsApp coaching and the monthly reviews with Dr Quek by continuing the monthly subscription, if they wish. If the weight starts coming back, they can come back to Dr Quek at any time: a restart begins with a review consultation, and whether to restart the medication is his decision at that review.
Designed to end: a programme whose pace and taper off the medication are planned from the first consult, so the result holds after the medication stops.
Common questions
What is the maintenance phase after GLP-1 medication?
The period after active weight loss ends, when the goal changes from losing more to holding what has been lost. Once the medication stops, it is also the period in which whatever behaviour is already in place has to hold the result on its own.
Does appetite come back when you stop GLP-1 medication?
No withdrawal trial measured it. STEP 1's extension, STEP 4 and SURMOUNT-4 measured body weight and cardiometabolic markers, not appetite, hunger or intake. What is known is that the drug clears — semaglutide has an elimination half-life of about a week and is present in the circulation for roughly 5 to 7 weeks after a last 2.4 mg dose (DailyMed), tirzepatide about 5 to 6 days (DailyMed) — so the appetite effect stops being produced. That is an inference from pharmacology rather than a measured trial outcome.
How much weight comes back after stopping?
In the STEP 1 extension, where the medication and the lifestyle support stopped on the same day with no taper, about two-thirds of the lost weight returned within a year, and the group finished 5.6% below its original starting weight (Wilding 2022). That overnight stop is the scenario a planned taper is designed around. Individual results vary widely — the STEP 1 figure carries a standard deviation of 7.7 percentage points.
How does GetLean bring the dose down?
Gradually, at Dr Quek's monthly reviews, rather than stopping it overnight, as the STEP 1 extension did. The taper is planned from the first consultation and set at the monthly reviews as the response comes in, towards the lowest effective dose, which allows appetite to adjust incrementally while the habits take over. Any dose change is a decision for the doctor who prescribed it; never change or stop a prescribed medication on your own.
What do people who keep weight off actually do?
Registry data points at a short list: a consistent eating pattern, a high level of physical activity — around an hour a day in the National Weight Control Registry (Klem 1997) — and continued self-weighing (Butryn 2007). That registry is a self-selected group of people who had already succeeded, so it describes what successful maintainers report rather than proving what causes success.
How much exercise does maintenance take?
The ACSM position stand associates more than 250 minutes a week with improved maintenance, on cross-sectional and prospective evidence (ACSM 2009).
Does weighing yourself regularly help?
It is associated with better outcomes. Among 3,003 registry members, 82% of whom completed a year of follow-up, those who weighed themselves less often gained 4.0 kg against 1.1 kg for those who weighed more often (Butryn 2007). Observational rather than causal.
Does maintenance get easier over time?
The evidence suggests so. Having held a loss for two years or more was associated with lower regain risk over the following year (McGuire 1999), and holding it two to five years substantially improves the odds (Wing 2001).
Do the National Weight Control Registry findings apply to people who lost weight on medication?
The registry predates GLP-1 medication, but a trial on medication points the same way. In a Copenhagen randomised trial that followed adults for a year after treatment ended, those who had combined a GLP-1 medication with supervised exercise were more likely than those who had taken the medication alone to still hold a loss of at least 10% of their starting weight (Jensen 2024). The medication was liraglutide, an earlier GLP-1 medicine, and the initial loss came from a low-calorie diet.
What happens after the taper at GetLean?
A patient can keep the daily WhatsApp coaching and the monthly reviews with Dr Quek by continuing the monthly subscription, if they wish. If the weight starts coming back, they can come back to Dr Quek at any time; a restart begins with a review consultation, and whether to restart the medication is his decision.